Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets slip further
Tue, 2 Dec 01:30 pm

With RBI maintaining status quo at its monthly policy review, Indian share markets slipped deeper in the red in the post-noon trading session. Sectoral indices are trading mixed with metal and pharma being the biggest gainers. Auto and IT stocks are the biggest losers today.

BSE-Sensex is down 114 points and NSE-Nifty is trading 38 points down. BSE Mid Cap is trading 0.4% up and BSE Small Cap index is trading up by 0.1%. The rupee is trading at 61.93 to the US dollar.

Most of the domestic pharma stocks are trading in the green led by Wockhardt and Cadila Healthcare. As per a leading financial daily, Ranbaxy has introduced the first biosimilar version of a drug used for the treatment of various conditions including rheumatoid arthritis in the Indian markets. The drug Infimab which is the biosimilar version of Johnson and Johnson's Remicade has been launched through a licensing partnership with Epirus Pharmaceuticals. The drug will be manufactured by Reliance Life Sciences at its Mumbai facility. Ranbaxy stock is trading marginally up.

Majority of the FMCG stocks are trading in the green with Lakshmi Energy and Marico being the major gainers whereas Pidilite and Emami are trading in the red. As per research agency Nielsen, private label brands offered by retailers are slowly gaining acceptance. Private labels in FMCG grew by 27% during the period 2012 and September 2014. About 5% of all modern trade sales comes from private labels whereas modern trade channel accounts for 9% of the overall FMCG industry in India. Private label brands not only offer a cheaper alternative but they also coax consumers to upgrade from loose to packaged products. Private label brands in India mostly succeed in commodity-driven, high-purchase items such as ghee, rice and wheat flour. As per Nielsen, with private label brands gaining traction, established brands should increase focus on innovation to differentiate and prevent shoppers from switching.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip further". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.